Clinical Trial

Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer

Study acronym: IREKI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-03-29; most recent amendment 2025-02-11.
Status change: Not Yet Recruiting → Recruiting 2021-06-15
Trial Details
NCT Number NCT04823923
Lead Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Collaborators: Ligue contre le cancer, France
Conditions Kidney Neoplasm
Enrollment 60 participants
Start Date 2021-12-06
Primary Completion 2026-01 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-02-12